Literature DB >> 17472227

Rates of decline distinguish Alzheimer's disease and mild cognitive impairment relative to normal aging: integrating cognition and brain function.

Belinda J Liddell1, Robert H Paul, Martijn Arns, Norman Gordon, Matthew Kukla, Donald Rowe, Nick Cooper, Jonson Moyle, Leanne M Williams.   

Abstract

AIMS: Increasing age is the strongest risk factor for Alzheimer's disease (AD). Yet, departure from normal age-related decline for established markers of AD including memory, cognitive decline and brain function deficits, has not been quantified.
METHODS: We examined the cross-sectional estimates of the "rate of decline" in cognitive performance and psychophysiological measures of brain function over age in AD, preclinical (subjective memory complaint-SMC, Mild Cognitive Impairment-MCI) and healthy groups. Correlations between memory performance and indices of brain function were also conducted.
RESULTS: The rate of cognitive decline increased between groups: AD showed advanced decline, and SMC/MCI groups represented intermediate stages of decline relative to normal aging expectations. In AD, advanced EEG alterations (excessive slow-wave/reduced fast-wave EEG, decreased working memory P450 component) were observed over age, which were coupled with memory decline. By contrast, MCI group showed less severe cognitive changes but specific decreases in the working memory N300 component and slow-wave (delta) EEG, associated with decline in memory. DISCUSSION AND INTEGRATIVE SIGNIFICANCE: While the cognitive data suggests a continuum of deterioration associated with increasing symptom severity across groups, integration with brain function measures points to possible distinct compensatory strategies in MCI and AD groups. An integrative approach offers the potential for objective markers of the critical turning point, with age as a potential factor, from mild memory problems to disease.

Entities:  

Mesh:

Year:  2007        PMID: 17472227     DOI: 10.1142/s0219635207001374

Source DB:  PubMed          Journal:  J Integr Neurosci        ISSN: 0219-6352            Impact factor:   2.117


  10 in total

1.  Acute effects of methadone on EEG power spectrum and event-related potentials among heroin dependents.

Authors:  Farid Motlagh; Fatimah Ibrahim; Rusdi Rashid; Niusha Shafiabady; Tahereh Seghatoleslam; Hussain Habil
Journal:  Psychopharmacology (Berl)       Date:  2018-10-11       Impact factor: 4.530

Review 2.  Biomarkers in translational research of Alzheimer's disease.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  Neuropharmacology       Date:  2010-04-13       Impact factor: 5.250

Review 3.  Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease.

Authors:  Gregory A Jicha; Sarah A Carr
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Principal component analysis of FDG PET in amnestic MCI.

Authors:  Flavio Nobili; Dario Salmaso; Silvia Morbelli; Nicola Girtler; Arnoldo Piccardo; Andrea Brugnolo; Barbara Dessi; Stig A Larsson; Guido Rodriguez; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-22       Impact factor: 9.236

5.  EEG spectral phenotypes: heritability and association with marijuana and alcohol dependence in an American Indian community study.

Authors:  Cindy L Ehlers; Evelyn Phillips; Ian R Gizer; David A Gilder; Kirk C Wilhelmsen
Journal:  Drug Alcohol Depend       Date:  2009-09-12       Impact factor: 4.492

6.  Sleep and EEG Power Spectral Analysis in Three Transgenic Mouse Models of Alzheimer's Disease: APP/PS1, 3xTgAD, and Tg2576.

Authors:  Brianne A Kent; Stephen M Strittmatter; Haakon B Nygaard
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.

Authors:  Leanne M Williams; A John Rush; Stephen H Koslow; Stephen R Wisniewski; Nicholas J Cooper; Charles B Nemeroff; Alan F Schatzberg; Evian Gordon
Journal:  Trials       Date:  2011-01-05       Impact factor: 2.279

8.  Electroencephalographic Fractal Dimension in Healthy Ageing and Alzheimer's Disease.

Authors:  Fenne Margreeth Smits; Camillo Porcaro; Carlo Cottone; Andrea Cancelli; Paolo Maria Rossini; Franca Tecchio
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

9.  Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project.

Authors:  Leanne M Williams; Andrea N Goldstein-Piekarski; Nowreen Chowdhry; Katherine A Grisanzio; Nancy A Haug; Zoe Samara; Amit Etkin; Ruth O'Hara; Alan F Schatzberg; Trisha Suppes; Jerome Yesavage
Journal:  BMC Psychiatry       Date:  2016-03-15       Impact factor: 3.630

10.  Sleep/Wake Behavior and EEG Signatures of the TgF344-AD Rat Model at the Prodromal Stage.

Authors:  Matthias Kreuzer; Glenda L Keating; Thomas Fenzl; Lorenz Härtner; Christopher G Sinon; Ihab Hajjar; Vincent Ciavatta; David B Rye; Paul S García
Journal:  Int J Mol Sci       Date:  2020-12-05       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.